New Anti-Angiogenic Targeted Therapy in Advanced Renal Cell Carcinoma (RCC):Current Status and Future Prospects

E-ISSN： 1876-1038|3|2|97-103

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.3, Iss.2, 2008-05, pp. : 97-103

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Duration of Targeted Therapy for Metastatic Renal Cell Carcinoma: A Review of Current Practices

Oncology, Vol. 82, Iss. 4, 2012-03 ,pp. : 189-196

Karger

Access to resources Recommend Favorite

Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 2999-3006

John Wiley & Sons Inc

Access to resources Recommend Favorite

Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era

CANCER, Vol. 122, Iss. 19, 2016-10 ,pp. : 2988-2995

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients

Oncology, Vol. 84, Iss. 2, 2012-11 ,pp. : 115-122

Karger

Access to resources Recommend Favorite

Cranial Prophylactic Irradiation in Locally Advanced Non-Small Cell Lung Carcinoma: Current Status and Future Perspectives

Oncology, Vol. 76, Iss. 3, 2009-02 ,pp. : 220-228

Karger

Access to resources Recommend Favorite